CAR-T (Chimeric Antigen Receptors Cell Therapy)

Immune cells, called T-cells, are taken from a sample of the patient’s blood. They are then reprogrammed in the lab to recognise and destroy the patient’s cancer cells. This ’living therapy’ is then given to the patient.

In 2019, The Christie joined a group of 9 NHS hospitals approved to provide Chimeric Antigen Receptors Cell Therapy (CAR-T) for adults with large B-cell lymphoma and acute lymphoblastic leukaemia for children and young people up to the age of 25.

The Christie is pleased to announce this product as a standard of care and also for clinical trials. We have been treating patients with these cells since April 2019. 

If you have any queries about our CAR-T therapy services, please email:

Last updated: March 2023